CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study

被引：8

作者：

Sinn, Marianne

Liersch, Torsten

Gellert, Klaus

Messmann, Helmut

Bechstein, Wolf O.

Waldschmidt, Dirk

Jacobasch, Lutz

Wilhelm, Martin

Rau, Bettina M.

Gruetzmann, Robert

Weinmann, Arndt

Maschmeyer, Georg

Pelzer, Uwe

Stieler, Jens

Striefler, Jana Kaethe

Ghadimi, B. Michael

Bahra, Marcus

Oettle, Helmut

Doerken, Bernd

Riess, Hanno

机构：

[1] Charite, Med Oncol, D-13353 Berlin, Germany

[2] Univ Gottingen, Univ Med Ctr, Dept Gen Visceral & Pediat Surg, D-37073 Gottingen, Germany

[3] Sana Klinikum Lichtenberg, Dept Gen & Visceral Surg, Berlin, Germany

[4] Klinikum Augsburg, Dept Gastroenterol, Augsburg, Germany

[5] Univ Hosp Frankfurt, Dept Gen & Visceral Surg, Frankfurt, Germany

[6] Univ Cologne, Dept Gastroenterol & Hepatol, D-50931 Cologne, Germany

[7] Klinikum Nuernberg, Nurnberg, Germany

[8] Univ Med Rostock, Dept Gen Thorac Vasc & Transplantat Surg, Rostock, Germany

[9] Univ Klinikum Carl Gustav Carus, Dept Gen Thorac & Vasc Surg, Dresden, Germany

[10] Klinikum Johannes Gutenberg Univ, Dept Gastroenterol, Mainz, Germany

[11] Potsdam Klinikum, Potsdam, Germany

[12] Charite, Med Oncol, D-13353 Berlin, Germany

[13] Charite, Dept Gen Visceral & Transplantat Surg, Berlin, Germany

[14] Outpatient Dept Hematol Oncol, Friedrichshafen, Germany

[15] Charite, Campus Virchow Klinikum, Internist Onkol, D-13353 Berlin, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4007

引用

页数：1

共 50 条

[1] CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Sinn, Marianne
Bahra, Marcus
Liersch, Torsten
Gellert, Klaus
Messmann, Helmut
Bechstein, Wolf
Waldschmidt, Dirk
Jacobasch, Lutz
Wilhelm, Martin
Rau, Bettina M.
Gruetzmann, Robert
Weinmann, Arndt
Maschmeyer, Georg
Pelzer, Uwe
Stieler, Jens M.
Striefler, Jana K.
Ghadimi, Michael
Bischoff, Sven
Doerken, Bernd
Oettle, Helmut
Riess, Hanno
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3330 - +
[2] Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005
Wisniewski, Mathilde
Placide, Pierre-Alain
Granier, Sandra
Al Shatti, Yacoub
Al Qalaf, Shuaib
Bouattour, Mohamed
Lamuraglia, Michele
Hammel, Pascal
HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (05) : 399 - 402
[3] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
Bao, Philip Q.
Ramanathan, Ramesh K.
Krasinkas, Alyssa
Bahary, Nathan
Lembersky, Barry C.
Bartlett, David L.
Hughes, Steven J.
Lee, Kenneth K.
Moser, A. James
Zeh, Herbert J., III
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 1122 - 1129
[4] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
Philip Q. Bao
Ramesh K. Ramanathan
Alyssa Krasinkas
Nathan Bahary
Barry C. Lembersky
David L. Bartlett
Steven J. Hughes
Kenneth K. Lee
A. James Moser
Herbert J. Zeh
Annals of Surgical Oncology, 2011, 18 : 1122 - 1129
[5] Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
Philip Q. Bao
Ramesh K. Ramanathan
Alyssa Krasinkas
Nathan Bahary
Barry C. Lembersky
David L. Bartlett
Steven J. Hughes
Kenneth K. Lee
A. James Moser
Herbert J. Zeh
Annals of Surgical Oncology, 2011, 18 : 323 - 323
[6] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Heinrich, Stefan
Pestalozzi, Bernhard
Lesurtel, Mickael
Berrevoet, Frederik
Laurent, Stephanie
Delpero, Jean-Robert
Raoul, Jean-Luc
Bachellier, Phillippe
Dufour, Patrick
Moehler, Markus
Weber, Achim
Lang, Hauke
Rogiers, Xavier
Clavien, Pierre-Alain
BMC CANCER, 2011, 11
[7] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Stefan Heinrich
Bernhard Pestalozzi
Mickael Lesurtel
Frederik Berrevoet
Stéphanie Laurent
Jean-Robert Delpero
Jean-Luc Raoul
Phillippe Bachellier
Patrick Dufour
Markus Moehler
Achim Weber
Hauke Lang
Xavier Rogiers
Pierre-Alain Clavien
BMC Cancer, 11
[8] CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)
Riess, H.
Neuhaus, P.
Post, S.
Gellert, K.
Ridwelski, K.
Schramm, H.
Zuelke, C.
Fahlke, J.
Langrehr, J.
Oettle, H.
ANNALS OF ONCOLOGY, 2008, 19 : 45 - 46
[9] CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)
Neuhaus, P.
Riess, H.
Post, S.
Gellert, K.
Ridwelski, K.
Schramm, H.
Zuelke, C.
Fahlke, J.
Langrehr, J.
Oettle, H.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, David
Chau, Ian
Stocken, Deborah D.
Valle, Juan W.
Smith, David
Steward, William
Harper, Peter G.
Dunn, Janet
Tudur-Smith, Catrin
West, Julia
Falk, Stephen
Crellin, Adrian
Adab, Fawzi
Thompson, Joyce
Leonard, Pauline
Ostrowski, Joe
Eatock, Martin
Scheithauer, Werner
Herrmann, Richard
Neoptolemos, John P.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5513 - 5518

← 1 2 3 4 5 →